** Shares of Integral Diagnostics IDX.AX rise 4.7% to A$2.25
** Citi upgrades healthcare facilities provider to 'Buy' from 'Neutral,' keeps PT unchanged at A$2.70
** Brokerage forecasts higher revenue and margins for IDX in FY26, buoyed by partial MRI de-regulation, potential lung cancer screening contract, and benefits from Capitol Health merger
** Stock rose 5.1% earlier in the session
** 13 analysts rate the stock "buy" or higher and 1 "hold"; their mean PT is A$3.13 – LSEG
** Including session's gains, stock trims YTD decline to 22.3%
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。